A Phase 3 interventional study of MK0653, ezetimibe / Duration of Treatment: 27 Weeks and MK0733, simvastatin / Duration of Treatment: 27 Weeks in Coronary Disease, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Coronary Disease by Organon & Co. — none open to participants now, none under way, none of them phase 3. Coronary Disease · Organon & Co..
Among the 12 studies in Coronary Disease by Organon & Co., this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2002, is one of 7 in phase 3, and was the 9th registered.
1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.
Browse Coronary Disease studies →None of the 12 studies in Coronary Disease by Organon & Co. is open now. The open studies under Coronary Disease, anywhere →
Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2002.
This study's enrollment of 616 is above the median of 160 across 779 interventional studies indexed under Coronary Disease.
Median enrollment 391 across the 10 interventional studies, 634 across the 2 observational. Of the 12 that completed or were terminated, 3 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Coronary Disease by Organon & Co., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to determine if the administration of ezetimibe and simvastatin together is more effective than simvastatin alone in lowering LDL-C levels to a goal of \<100 mg/dL in patients at risk for Heart Disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LDL-C measurement (target goal = <100 mg/dL)
Time frame: 27 Weeks
Well tolerated in patients
Time frame: 27 Weeks
No study locations are listed for this record.
The record gives a start of Jan 2002, a primary completion of Mar 2003 and a completion of Mar 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.